What if the Women's Health Initiative had used transdermal estradiol and oral progesterone instead?

Menopause

Volumn 21, Issue 7, 2014, Pages 769-783

  Simon, James A ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Hormone therapy; Menopause; Micronized progesterone; Transdermal estradiol; Venous thromboembolism; Women's Health Initiative

Indexed keywords

ESTRADIOL; MEDROXYPROGESTERONE ACETATE; PROGESTERONE;

BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; HORMONAL THERAPY; HUMAN; REVIEW; RISK ASSESSMENT; RISK FACTOR; VENOUS THROMBOEMBOLISM; WOMEN'S HEALTH; ADULT; BREAST TUMOR; CHEMICALLY INDUCED; DOSE RESPONSE; ESTROGEN THERAPY; FEMALE; HOT FLASHES; INTRADERMAL DRUG ADMINISTRATION; MENOPAUSE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOT FLASHES; HUMANS; MEDROXYPROGESTERONE ACETATE; MENOPAUSE; MIDDLE AGED; PROGESTERONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM; WOMEN'S HEALTH;

EID: 84903216982     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000000169     Document Type: Review

References (97)

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333. (Pubitemid 34761611)
2. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712. (Pubitemid 38489892)
3. Vagifem [package insert]. Bagsvaerd Denmark: Novo Nordisk A/S; 2003-2010. Available at: http://www.novo-pi.com/vagifem.pdf. Accessed November 28, 2012.
4. L'Hermite M, Simoncini T, Fuller S, Genazzani AR. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. Maturitas 2008;60:185-201.
5. Modena MG, Sismondi P, Mueck AO, et al. New evidence regarding hormone replacement therapies is urgently required transdermal post-menopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas 2005;52:1-10. (Pubitemid 41242736)
6. The North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:242-255.
7. Rijpkema AH, van der Sanden AA, Ruijs AH. Effects of post-menopausal oestrogen-progestogen replacement therapy on serum lipids and lipopro-teins: a review. Maturitas 1990;12:259-285. (Pubitemid 20279933)
8. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
9. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-1037.
10. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-941. (Pubitemid 32003509)
11. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
12. Barrett-Connor E, Slone S, Greendale G, et al. The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women. Maturitas 1997;27:261-274. (Pubitemid 27356259)
13. Espeland MA, Stefanick ML, Kritz-Silverstein D, et al. Effect of post-menopausal hormone therapy on body weight and waist and hip girths. Postmenopausal Estrogen-Progestin Interventions Study Investigators. J Clin Endocrinol Metab 1997;82:1549-1556. (Pubitemid 27200433)
14. Langer RD. Postmenopausal Estrogen/Progestin Interventions Trial (PEPI). In: D'Agostino RB, Sullivan L, Joseph Massaro J, eds. Wiley Encyclopedia of Clinical Trials. Hoboken, NJ: John Wiley and Sons, Inc, 2008.
15. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534. (Pubitemid 36951364)
16. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy post-menopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-3253. (Pubitemid 37430077)
17. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-2684. (Pubitemid 37430138)
18. Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-1580. (Pubitemid 39314963)
19. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357-365. (Pubitemid 43244325)
20. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006;113:2425-2434. (Pubitemid 43948050)
21. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006; 166:772-780.
22. Olié V, Canonico M, Scarabin PY. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol 2010;17:457-463.
23. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011; 305:1305-1314.
24. National Heart, Lung, and Blood Institute (NHLBI). Incidence and Prevalence: 2006 Chart Book on Cardiovascular and Lung Diseases. Available at: http://www.nhlbi.nih.gov/resources/docs/06a-ip-chtbk.pdf. Accessed November 28, 2012.
25. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006;15:35-44. (Pubitemid 43192860)
26. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006;21: 363-366.
27. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477. (Pubitemid 46556472)
28. Hodis HM. Assessing benefits and risks of hormone therapy in 2008: new evidence, especially with regard to the heart. Cleve Clin J Med 2008; 75:S3-S12.
29. Schenck-Gustafsson K, Brincat M, Erel CT, et al. EMAS position statement: managing the menopause in the context of coronary heart disease. Maturitas 2011;68:94-97.
30. Taylor HS, Manson JE. Update in hormone therapy use in menopause. J Clin Endocrinol Metab 2011;96:255-264.
31. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036-1045. (Pubitemid 351347060)
32. Baber RJ. Health outcomes in postmenopausal women with prior hysterectomy after stopping CEE therapy. Menopause Live. IMS Updates. May 9, 2011. Available at: http://www.imsociety.org/updates-view-open.php?menopauseliveID= 1165&SESSID=7o617501sipnf6gjjpjblsa2h1.
33. Fournier A. Should transdermal rather than oral estrogens be used in menopausal hormone therapy? A review. Menopause Int 2010;16:23-32.
34. LLkkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Lidegaard O. Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J 2008;29:2660-2668.
35. Vongpatanasin W, Tuncel M, Wang Z, Arbique D, Mehrad B, Jialal I. Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol 2003;41:1358-1363. (Pubitemid 36438997)
36. Hemelaar M, van der Mooren MJ, Rad M, Kluft C, Kenemans P. Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review. Fertil Steril 2008;90:642-672.
37. Boschitsch E, Mayerhofer S, Magometschnigg D. Hypertension in women: the role of progesterone and aldosterone. Climacteric 2010;13: 307-313.
38. Ashraf MS, Vongpatanasin W. Estrogen and hypertension. Curr Hypertens Rep 2006;8:368-376. (Pubitemid 44463720)
39. Rylance PB, Brincat M, Lafferty K, et al. Natural progesterone and antihypertensive action. BMJ 1985;290:13-14. (Pubitemid 15075974)
40. Hassager C, Riis BJ, StrLm V, Guyene TT, Christiansen C. The long-term effect of oral and percutaneous estradiol on plasma renin substrate and blood pressure. Circulation 1987;76:753-758. (Pubitemid 17151332)
41. Lee DY, Kim JY, Kim JH, et al. Effects of hormone therapy on ambulatory blood pressure in postmenopausal Korean women. Climacteric 2011;14:92-99.
42. Rosano M, Vitale C, Silvestri A, Fini M. Metabolic and vascular effect of progestins in post-menopausal women. Implications for cardioprotection. Maturitas 2003;46(suppl 1):S17-S29. (Pubitemid 37506059)
43. de Lauzon-Guillain B, Fournier A, Fabre A, et al. Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle Générale de l'Education Nationale (E3N) cohort. Diabetologia 2009;52:2092-2100.
44. Chu MC, Cosper P, Nakhuda GS, Lobo RA. A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome. Fertil Steril 2006;86:1669-1675.
45. Rossouw J, Bray P, Liu J, et al. Estrogen receptor polymorphisms and the vascular effects of hormone therapy. Arterioscler Thromb Vasc Biol 2011;31:464-469.
46. Lobo RA, Clarkson TB. Different mechanisms for benefit and risk of coronary heart disease and stroke in early postmenopausal women: a hypothetical explanation. Menopause 2011;18:237-240.
47. Grodstein F, Manson JE, Stampfer MJ, Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 2008;168:861-866. (Pubitemid 351620088)
48. Sare GM, Gray LJ, Bath PM. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 2008;29:2031-2041.
49. Renoux C, Dell'aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010;340:c2519.
50. Olié V, Plu-Bureau G, Conard J, Horellou MH, Canonico M, Scarabin PY. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause 2011;18:488-493.
51. Canonico M, Bouaziz E, Carcaillon L, et al. Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women. J Clin Endocrinol Metab 2008;93:3082-3087.
52. Bagot CN, Marsh MS, Whitehead M, et al. The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy. J Thromb Haemost 2010;8:1736-1744.
53. Lobo RA. Risk of venous thromboembolism by route of administration of estrogen. Menopause 2011;18:469-470.
54. Scarabin PY, Alhene-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997;17:3071-3078. (Pubitemid 28016061)
55. Post MS, Christella M, Thomassen LG, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003;23:1116-1121. (Pubitemid 36713570)
56. Oger E, Alhene-Gelas M, Lacut K, et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 2003;23:1671-1676. (Pubitemid 37108215)
57. Scarabin PY, Oger E, Plu-Bureau G, EStrogen and THromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-432. (Pubitemid 36999704)
58. Straczek C, Oger E, Yon de Jonage-Canonico MB, et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005;112:3495-3500. (Pubitemid 43739566)
59. Tremollieres F, Brincat M, Erel CT, et al. EMAS position statement: managing menopausal women with a personal or family history of VTE. Maturitas 2011;69:195-198.
60. Canonico M, Oger E, Conard J, et al. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost 2006;4:1259-1265.
61. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER Study. Circulation 2007;115:840-845. (Pubitemid 46294724)
62. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008;336:1227-1231. (Pubitemid 351809317)
63. Canonico M, Plu-Bureau G, Scarabin PY. Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. Maturitas 2011;70:354-360.
64. Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost 2010;8:979-986.
65. Laliberté F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause 2011;18:1052-1059.
66. Kahler KH, Nyirady J, Beresford E, et al. Does route of administration for estrogen hormone therapy and estradiol transdermal system dosage strength impact risk of venous thromboembolism. Paper presented at: NAMS 22nd Annual Meeting; September 23, 2011; Washington, DC.
67. Roach RE, Lijfering WM, Helmerhorst FM, et al. The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy. J Thromb Haemost 2013;11:124-131.
68. Sweetland S, Beral V, Balkwill A, et al; The Million Women Study Collaborators. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study [published online ahead of print September 10, 2012]. J Thromb Haemost. doi: 10.1111/j.1538-7836.2012.04919.x.
69. Canonico M, Alhenc-Gelas M, Plu-Bureau G, Olié V, Scarabin PY. Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen. Menopause 2010;17:1122-1127.
70. American Cancer Society. Breast cancer facts & figures, 2009-2010. Available at: http://www.cancer.org/acs/groups/content/@nho/documents/document/ f861009final90809pdf.pdf. Accessed November 28, 2012.
71. National Heart, Lung, and Blood Institute (NHLBI). Leading causes of death for American Women; 2007. Available at: http://www.nhlbi.nih.gov/ educational/hearttruth/downloads/pdf/infographic-leadingcauses.pdf. Accessed November 28, 2012.
72. Society for Women's Health Research (SWHR). Women's fear of heart disease has almost doubled in three years, but breast cancer remains most feared disease: new survey shows what diseases women fear most; July 7, 2005. Available at: http://www.womenshealthresearch.org/site/News2?page=NewsArticle&id= 5459&news-iv-ctrl=0&abbr=press-. Accessed November 28, 2012.
73. Bluming AZ, Tavris C. Hormone replacement therapy: real concerns and false alarms. Cancer J 2009;15:93-104.
74. Berman RS, Epstein RS, Lydick E. Risk factors associated with women's compliance with estrogen replacement therapy. J Womens Health 1997;6:219-226.
75. Pollycove R. Individualizing hormone supplementation/replacement therapy. San Francisco Medical Society Web site; April 2011. Available at: http://www.sfms.org/ForPatients/PhysicianFinder/PhysicianInfo/tabid/506/ customercd/176079/Default.aspx. Accessed November 28, 2012.
76. Shapiro S, Farmer RD, Mueck AO, Seaman H, Stevenson JC. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies, 3: the Women's Health Initiative: unopposed estrogen. J Fam Plann Reprod Health Care 2011;37:225-230.
77. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103-111. (Pubitemid 350179584)
78. Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol 2009;27:5138-5143.
79. Stanczyk FZ. All steroids are not created equal. Steroids 2003;68:879-890. (Pubitemid 37532412)
80. Sitruk-Ware R. Pharmacological profile of progestogens. Maturitas 2008; 61:151-157.
81. Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Cline JM. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat 2007;101:125-134. (Pubitemid 46115419)
82. Courtin A, Communal L, Vilasco M, et al. Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. Breast Cancer Res Treat 2012;131:49-63.
83. Harvey J, Scheurer C, Kawakami FT, Quebe-Fehling E, de Palacios PL, Ragavan VV. Hormone replacement therapy and breast density changes. Climacteric 2005;8:185-192. (Pubitemid 40862995)
84. Lippert C, Seeger H, Mueck AO. The effect of endogenous estradiol metabolites on the proliferation of human breast cancer cells. Life Sci 2003;72:877-883. (Pubitemid 35454133)
85. Lippert TH, Seeger H, Mueck AO. Estradiol metabolism during oral and transdermal estradiol replacement therapy in postmenopausal women. Horm Metab Res 1998;30:598-600. (Pubitemid 28459625)
86. Mueck AO, Seeger H, Lippert TH. Estradiol metabolism and malignant disease. Maturitas 2002;43:1-10. (Pubitemid 35254059)
87. Murkes D, Conner P, Leifland K, et al. Effects of percutaneous estradiolYoral progesterone versus oral conjugated equine estrogensYmedroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women. Fertil Steril 2011;95:1188-1191.
88. Santen RJ, Petroni GR. Relative versus attributable risk of breast cancer from estrogen replacement therapy. J Clin Endocrinol Metab 1999;84: 1875-1881. (Pubitemid 30647002)
89. Fleiss JL, Levin B, Paik MC. Statistical Methods for Rates and Proportions, 3rd ed. New York: Wiley Interscience, 2003:125-129, 151-154.
90. Hanley JA. A heuristic approach to the formulas for population attributable fraction. J Epidemiol Community Health 2001;55:508-514. (Pubitemid 32591907)
91. Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30:340-345.
92. Sturdee DW, Pines A, International Menopause Society Writing Group, et al. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011;14: 302-320.
93. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95:s1-s66.
94. Tsai SA, Stefanick ML, Stafford RS. Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009. Menopause 2011; 18:385-392.
95. Sarrel PM, Njike VY, Vinante V, Katz DL. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. Am J Public Health 2013;103:1583-1588.
96. Hodis HN. Is ET avoidance associated with early death in women with hysterectomy? Comment #2. In: First to Know. The North American Menopause Society. July 26, 2013. Available at: http://www.menopause.org/docs/default- source/professional/news0713special.pdf.
97. Utian WH. A decade post WHI, menopausal hormone therapy comes full circleVneed for independent commission. Climacteric 2012;15:320-325.